Aravive to Participate in Fireside Chat at 2021 William Blair Biotech Focus Conference

Rhea-AI Summary

Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company, will participate in a virtual fireside chat and one-on-one meetings at the 2021 William Blair Biotech Focus Conference on July 15, 2021, at 3:00 PM ET. CEO Gail McIntyre and CMO Reshma Rangwala will be featured speakers. The event will be accessible via a live webcast, with archived replays available for 90 days. Aravive is developing AVB-500, a therapeutic targeting the GAS6-AXL signaling pathway, currently in clinical trials for ovarian and renal cell cancers, and planning a trial for pancreatic cancer in late 2021.

HOUSTON, July 07, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that Gail McIntyre, Ph.D., DBAT, Chief Executive Officer of Aravive, and Reshma Rangwala, M.D., Ph.D., Chief Medical Officer of Aravive, will participate in a virtual fireside chat at the 2021 William Blair Biotech Focus Conference on July 15, 2021, at 3:00 PM ET. Aravive will also be participating in one-on-one meetings at the conference.

This meeting is being held virtually, and a live webcast will be accessible on the Events & Presentations page of https://aravive.com/. Archived replays of the webcasts will be available for 90 days following the presentations.

About Aravive
Aravive, Inc. is a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases. Aravive’s lead therapeutic, AVB-500, is a first-in-class ultra-high affinity decoy protein that targets the GAS6-AXL signaling pathway associated with tumor cell growth, tumor metastasis, resistance to treatment and decreased survival. AVB-500 has the potential to be combined with multiple anti-cancer therapies across several tumor types, due to its novel mechanism of action and favorable safety profile. AVB-500 has been granted Fast Track Designation by the U.S. Food and Drug Administration in platinum resistant recurrent ovarian cancer. The Company is currently evaluating AVB-500 in a registrational Phase 3 trial in platinum resistant ovarian cancer and a Phase 1b/2 trial in clear cell renal cell carcinoma. Aravive plans to initiate a Phase 1b/2 trial evaluating AVB-500 in first-line treatment of pancreatic cancer in the second half of 2021. The Company is based in Houston, Texas and received a Product Development Award from the Cancer Prevention & Research Institute of Texas (CPRIT) in 2016. For more information, please visit www.aravive.com.

Contact:
Joseph T. Schepers
VP, Investor Relations, Aravive, Inc.
jschepers@aravive.com
(770) 558-5517

FAQ

What is Aravive's participation in the William Blair Biotech Focus Conference on July 15, 2021?

Aravive will participate in a virtual fireside chat and one-on-one meetings, featuring CEO Gail McIntyre and CMO Reshma Rangwala.

What time is Aravive's presentation at the conference?

Aravive's presentation is scheduled for July 15, 2021, at 3:00 PM ET.

Where can I watch the Aravive webcast from the conference?

The webcast will be available on Aravive's Events & Presentations page, with archived replays for 90 days.

What is the focus of Aravive's lead therapeutic, AVB-500?

AVB-500 targets the GAS6-AXL signaling pathway associated with tumor growth and resistance to treatment.

What clinical trials is Aravive currently conducting for AVB-500?

Aravive is evaluating AVB-500 in a Phase 3 trial for platinum-resistant ovarian cancer and a Phase 1b/2 trial for clear cell renal cell carcinoma.